Clinical Chemistry, Vol 34, 2048-2052, Copyright © 1988 by American Association for Clinical Chemistry

Electroimmuno- and immunonephelometric assays of apolipoprotein A-I by using a mixture of monoclonal antibodies

I Pruvot, C Fievet, C Durieux, N Vu Dac and JC Fruchart
Service de Recherches sur les Lipoproteines et l'Atherosclerose (SERLIA) et INSERM U279, Institut Pasteur, Lille, France.

The use of mixtures of well-defined monoclonal antibodies may represent a step forward in the standardization of immunochemical assays. We developed and optimized working conditions for using such a mixture to determine apolipoprotein A-I in human sera by two independent techniques (electroimmuno- and immunonephelometric-assays). Six monoclonal antibodies, each addressed to distinct epitopes located at the surface of apolipoprotein A-I, were used in combination to permit a reproducible measurement of the protein, without prior delipidation of samples. Parallel standard curves for a high-density lipoprotein subfraction (HDL3, the primary standard) and a reference serum (the secondary standard) were obtained. Within- and between-run coefficients of variation were acceptable for both methods. Apolipoprotein A-I concentrations, as measured in 60 subjects selected to present a large range of apolipoprotein content by electroimmunoassay (y1) and immunonephelometric assay (y2) with monoclonal antibodies, compared well with those measured by the same techniques but with polyclonal antibodies (x): r1 = 0.96, r2 = 0.99; y1 = 1.19x - 0.11 g/L, y2 = 0.98x. Comparison of results obtained by electroimmunoassay and immunonephelometric assay performed with monoclonal antibodies was also good: r = 0.96; y2 = 1.08y1 + 0.13 g/L.

The following articles in journals at HighWire Press have cited this article:

				G. K. Hovingh, B. A. Hutten, A. G. Holleboom, W. Petersen, P. Rol, A. Stalenhoef, A. H. Zwinderman, E. de Groot, J. J.P. Kastelein MD, and J. A. Kuivenhoven Compromised LCAT Function Is Associated With Increased Atherosclerosis Circulation, August 9, 2005; 112(6): 879 - 884. [Abstract] [Full Text] [PDF]

				Y. Stein, O. Stein, N. Duverger, G. Halperin, Y. Dabach, G. Hollander, and M. Ben-Naim Clearance of Cationized LDL Cholesterol From a Muscle Depot Is Not Enhanced in Human Apolipoprotein A-IV Transgenic Mice Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 179 - 184. [Abstract] [Full Text] [PDF]

				B. E. Cham, J. L. Smith, and D. M. Colquhoun What Happens to Vitamin K1 in Serum after Bone Fracture? Clin. Chem., December 1, 1999; 45(12): 2261 - 2263. [Full Text] [PDF]

				N. Duverger, C. Viglietta, L. Berthou, F. Emmanuel, A. Tailleux, L. Parmentier-Nihoul, B. Laine, C. Fievet, G. Castro, J. C. Fruchart, et al. Transgenic Rabbits Expressing Human Apolipoprotein A-I in the Liver Arterioscler Thromb Vasc Biol, December 1, 1996; 16(12): 1424 - 1429. [Abstract] [Full Text]

				N. Duverger, H. Kruth, F. Emmanuel, J.-M. Caillaud, C. Viglietta, G. Castro, A. Tailleux, C. Fievet, J. C. Fruchart, L. M. Houdebine, et al. Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits Circulation, August 15, 1996; 94(4): 713 - 717. [Abstract] [Full Text]